Skip to main content

Table 2 Coagulation, platelet function, fibrinolysis and fibrin clot properties

From: Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk

 

LOWER glucose group (<4.5 mmol/l)

MEDIUM glucose group (4.5-6.0 mmol/l)

HIGHER glucose group (>6.0 mmol/l)

P-value

Fibrinogen, g/dL

3.06 (2.66-3.48)

3.13 (2.67-3.57)

3.15 (2.64-3.61)

0.98

Peak thrombin, nM

273 (209–380)

225 (201–268)*

236 (196–275)*

0.002

PF4

10.6 (9.1-12.8)

9.5 (8.2-12.0)

10.3 (8.2-12.8)

0.26

sCD40L

4.3 (3.6-4.9)

3.7 (3.1-4.4)

3.8 (3.3-4.8)

0.09

TAFI, %

71.5 (41.6-90.0)

91.0 (84.0-106.0)*

100.0 (92.0-111.0)*

<0.0001

PAI-1: Ag

30.6 (25.8-36.1)

32.0 (28.7-36.3)

33.9 (29.4-38.9)

0.23

Plasminogen, %

109 ± 21

108 ± 16

110 ± 14

0.83

Antiplasmin, %

109 (100–118)

109 (96–118)

107 (97–117)

0.61

Ks, cm2x10−9

6.52 ± 0.79

7.29 ± 0.81*

7.06 ± 0.88*

0.0001

t50%, min

10.49 ± 0.97

9.55 ± 0.91*

9.79 ± 1.11*

<0.0001

Lag_phase, s

45 (41–50)

44 (41–47.0)

43 (40–45)*

0.019

ΔAbsmax, 405 nm

0.79 (0.76-0.83)

0.81 (0.77-0.86)

0.82 (0.80-0.87)*

0.015

D-Drate mg/L/min

0.069 ± 0.006

0.070 ± 0.005

0.07 ± 0.004

0.47

D-Dmax mg/L

3.90 (3.78-4.22)

3.87 (3.69-4.06)

3.88 (3.62-4.22)

0.30

  1. Values are given as mean ± SD, median (interquartile range). P value was measured using analysis of variance (ANOVA) with post-hoc Bonferroni test or Kruskal-Wallis test with multiple comparisons of mean rank, *p < 0.05 as compared with LOWER glucose group.
  2. Abbreviations: ΔAbsmax, maximum absorbance of fibrin gel at 405 nm determined by using turbidimetry; sCD40L, soluble CD40 ligand; D-Dmax, maximum D-dimer levels in the lysis assay; D-Drate, maximum rate of increase in D-dimer levels in the lysis assay; Ks, permeability coefficient; PAI-1: Ag; plasminogen activator inhibitor-1 antigen; PF4, platelet factor 4; t50%, half-lysis time; TAFI, thrombin-activatable fibrinolysis inhibitor.